{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T09:30:42Z","timestamp":1769592642134,"version":"3.49.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lipids Health Dis"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12944-017-0621-4","type":"journal-article","created":{"date-parts":[[2017,12,2]],"date-time":"2017-12-02T03:08:24Z","timestamp":1512184104000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Non-HDL cholesterol and LDL cholesterol in the dyslipidemic classification in patients with nonalcoholic fatty liver disease"],"prefix":"10.1186","volume":"16","author":[{"given":"Tingting","family":"Du","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingxing","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuefeng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,12,2]]},"reference":[{"issue":"6","key":"621_CR1","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/hep.20466","volume":"40","author":"JD Browning","year":"2004","unstructured":"Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40(6):1387\u201395.","journal-title":"Hepatology"},{"issue":"3","key":"621_CR2","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1365-2036.2011.04724.x","volume":"34","author":"G Vernon","year":"2011","unstructured":"Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34(3):274\u201385.","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"621_CR3","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1002\/hep.23593","volume":"51","author":"EK Speliotes","year":"2010","unstructured":"Speliotes EK, Massaro JM, Hoffmann U, Vasan RS, Meigs JB, Sahani DV, et al. Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: the Framingham heart study. Hepatology. 2010;51(6):1979\u201387.","journal-title":"Hepatology"},{"issue":"9756","key":"621_CR4","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1016\/S0140-6736(10)61272-X","volume":"376","author":"VG Athyros","year":"2010","unstructured":"Athyros VG, Tziomalos K, Gossios TD, Griva T, Anagnostis P, Kargiotis K, et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and coronary heart disease evaluation (GREACE) study: a post-hoc analysis. Lancet. 2010;376(9756):1916\u201322.","journal-title":"Lancet"},{"issue":"5","key":"621_CR5","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1053\/gast.2002.36569","volume":"123","author":"American Gastroenterological Association","year":"2002","unstructured":"American Gastroenterological Association. American Gastroenterological Association medical position statement: nonalcoholic fatty liver disease. Gastroenterology. 2002;123(5):1702\u20134.","journal-title":"Gastroenterology"},{"issue":"5","key":"621_CR6","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1185\/030079906X104696","volume":"22","author":"VG Athyros","year":"2006","unstructured":"Athyros VG, Mikhailidis DP, Didangelos TP, Giouleme OI, Liberopoulos EN, Karagiannis A, et al. Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Curr Med Res Opin. 2006;22(5):873\u201383.","journal-title":"Curr Med Res Opin"},{"issue":"9","key":"621_CR7","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.tem.2011.04.007","volume":"22","author":"SH Choi","year":"2011","unstructured":"Choi SH, Ginsberg HN. Increased very low density lipoprotein (VLDL) secretion, hepatic steatosis, and insulin resistance. Trends Endocrinol Metab. 2011;22(9):353\u201363.","journal-title":"Trends Endocrinol Metab"},{"issue":"2","key":"621_CR8","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.atherosclerosis.2013.01.022","volume":"227","author":"AP DeFilippis","year":"2013","unstructured":"DeFilippis AP, Blaha MJ, Martin SS, Reed RM, Jones SR, Nasir K, et al. Nonalcoholic fatty liver disease and serum lipoproteins: the multi-ethnic study of atherosclerosis. Atherosclerosis. 2013;227(2):429\u201336.","journal-title":"Atherosclerosis"},{"issue":"6","key":"621_CR9","doi-asserted-by":"crossref","first-page":"e128","DOI":"10.1111\/liv.12318","volume":"34","author":"S Zelber-Sagi","year":"2014","unstructured":"Zelber-Sagi S, Salomone F, Yeshua H, Lotan R, Webb M, Halpern Z, et al. Non-high-density lipoprotein cholesterol independently predicts new onset of non-alcoholic fatty liver disease. Liver Int. 2014;34(6):e128\u201335.","journal-title":"Liver Int"},{"issue":"6","key":"621_CR10","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.cgh.2012.01.017","volume":"10","author":"KE Corey","year":"2012","unstructured":"Corey KE, Lai M, Gelrud LG, Misdraji J, Barlow LL, Zheng H, et al. Non-high-density lipoprotein cholesterol as a biomarker for nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2012;10(6):651\u20136.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"12","key":"621_CR11","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1001\/jama.2012.366","volume":"307","author":"SM Boekholdt","year":"2012","unstructured":"Boekholdt SM, Arsenault BJ, Mora S, Pedersen TR, LaRosa JC, Nestel PJ, et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA. 2012;307(12):1302\u20139.","journal-title":"JAMA"},{"issue":"2","key":"621_CR12","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.113.000759","volume":"3","author":"G Thanassoulis","year":"2014","unstructured":"Thanassoulis G, Williams K, Ye K, Brook R, Couture P, Lawler PR, et al. Relations of change in plasma levels of LDL-C, non-HDL-C and apoB with risk reduction from statin therapy: a meta-analysis of randomized trials. J Am Heart Assoc. 2014;3(2):e000759.","journal-title":"J Am Heart Assoc"},{"key":"621_CR13","doi-asserted-by":"crossref","unstructured":"Du T, Yu X, Yuan G, Zhang J, Sun X. Combined influence of nonalcoholic fatty liver and body size phenotypes on diabetes risk. Cardiovasc Diabetol. 2015;14144.","DOI":"10.1186\/s12933-015-0306-0"},{"key":"621_CR14","doi-asserted-by":"crossref","unstructured":"American Diabetes Association. (2) classification and diagnosis of diabetes. Diabetes Care. 2015;38(SupplS8\u2013S16).","DOI":"10.2337\/dc15-S005"},{"key":"621_CR15","first-page":"269","volume-title":"The urinary tract. Abdominal ultrasound","author":"C Mittelstaedt","year":"1987","unstructured":"Mittelstaedt C, Vincent L. The urinary tract. Abdominal ultrasound. 1st ed. New York: Churchill Livingston; 1987. p. 269.","edition":"1"},{"issue":"3","key":"621_CR16","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1053\/gast.2002.35354","volume":"123","author":"S Saadeh","year":"2002","unstructured":"Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology. 2002;123(3):745\u201350.","journal-title":"Gastroenterology"},{"issue":"19","key":"621_CR17","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","volume":"285","author":"Expert Panel on Detection Evaluation, And Treat ment of High Blood Cholesterol in Adults","year":"2001","unstructured":"Expert Panel on Detection Evaluation, And Treat ment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA. 2001;285(19):2486\u201397.","journal-title":"JAMA"},{"issue":"4","key":"621_CR18","doi-asserted-by":"crossref","first-page":"811","DOI":"10.2337\/dc08-9018","volume":"31","author":"JD Brunzell","year":"2008","unstructured":"Brunzell JD, Davidson M, Furberg CD, Goldberg RB, Howard BV, Stein JH, et al. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care. 2008;31(4):811\u201322.","journal-title":"Diabetes Care"},{"issue":"1","key":"621_CR19","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.numecd.2016.10.004","volume":"27","author":"T Du","year":"2017","unstructured":"Du T, Sun X, Yuan G, Zhou X, Lu H, Lin X, et al. Sex differences in the impact of nonalcoholic fatty liver disease on cardiovascular risk factors. Nutr Metab Cardiovasc Dis. 2017;27(1):63\u20139.","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"6","key":"621_CR20","doi-asserted-by":"crossref","first-page":"447","DOI":"10.7326\/0003-4819-135-6-200109180-00014","volume":"135","author":"AD Sniderman","year":"2001","unstructured":"Sniderman AD, Scantlebury T, Cianflone K. Hypertriglyceridemic hyperapob: the unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus. Ann Intern Med. 2001;135(6):447\u201359.","journal-title":"Ann Intern Med"},{"issue":"4","key":"621_CR21","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1055\/s-0033-1358519","volume":"33","author":"DE Cohen","year":"2013","unstructured":"Cohen DE, Fisher EA. Lipoprotein metabolism, dyslipidemia, and nonalcoholic fatty liver disease. Semin Liver Dis. 2013;33(4):380\u20138.","journal-title":"Semin Liver Dis"},{"issue":"1","key":"621_CR22","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jhep.2010.05.037","volume":"54","author":"P Simonen","year":"2011","unstructured":"Simonen P, Kotronen A, Hallikainen M, Sevastianova K, Makkonen J, Hakkarainen A, et al. Cholesterol synthesis is increased and absorption decreased in non-alcoholic fatty liver disease independent of obesity. J Hepatol. 2011;54(1):153\u20139.","journal-title":"J Hepatol"},{"issue":"3","key":"621_CR23","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/hep.23094","volume":"50","author":"K Fujita","year":"2009","unstructured":"Fujita K, Nozaki Y, Wada K, Yoneda M, Fujimoto Y, Fujitake M, et al. Dysfunctional very-low-density lipoprotein synthesis and release is a key factor in nonalcoholic steatohepatitis pathogenesis. Hepatology. 2009;50(3):772\u201380.","journal-title":"Hepatology"},{"issue":"7","key":"621_CR24","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1007\/s00535-010-0203-y","volume":"45","author":"Y Kimura","year":"2010","unstructured":"Kimura Y, Hyogo H, Yamagishi S, Takeuchi M, Ishitobi T, Nabeshima Y, et al. Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH. J Gastroenterol. 2010;45(7):750\u20137.","journal-title":"J Gastroenterol"},{"issue":"14","key":"621_CR25","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","volume":"32","author":"European Association for Cardiovascular Prevention and Rehabilitation, Reiner Z, Catapano AL, De Backer G, Graham I, et al.","year":"2011","unstructured":"European Association for Cardiovascular Prevention and Rehabilitation, Reiner Z, Catapano AL, De Backer G, Graham I, et al. ESC\/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European atherosclerosis society (EAS). Eur Heart J. 2011;32(14):1769\u2013818.","journal-title":"Eur Heart J"},{"issue":"2","key":"621_CR26","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.atherosclerosis.2014.07.019","volume":"236","author":"T Hisamatsu","year":"2014","unstructured":"Hisamatsu T, Fujiyoshi A, Miura K, Ohkubo T, Kadota A, Kadowaki S, et al. Lipoprotein particle profiles compared with standard lipids in association with coronary artery calcification in the general Japanese population. Atherosclerosis. 2014;236(2):237\u201343.","journal-title":"Atherosclerosis"}],"container-title":["Lipids in Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-017-0621-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,7]],"date-time":"2019-10-07T04:41:10Z","timestamp":1570423270000},"score":1,"resource":{"primary":{"URL":"https:\/\/lipidworld.biomedcentral.com\/articles\/10.1186\/s12944-017-0621-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["621"],"URL":"https:\/\/doi.org\/10.1186\/s12944-017-0621-4","relation":{},"ISSN":["1476-511X"],"issn-type":[{"value":"1476-511X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12]]},"article-number":"229"}}